Botulinum toxin E - Bonti

Drug Profile

Botulinum toxin E - Bonti

Alternative Names: BoNT/E; EB-001; EB-001A; EB-001T

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bonti
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glabellar lines; Musculoskeletal pain; Scars

Most Recent Events

  • 02 Aug 2018 Topline safety and efficacy data from the phase IIa SHINE-1 trial released by Bonti
  • 02 Aug 2018 Bonti completes the phase IIa SHINE-1 trial for Scars in USA
  • 09 May 2018 Bonti completes the phase II LANTERN-1 trial for Musculoskeletal pain in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top